ITHACA, N.Y. - 5/20/05 - A Cornell University researcher won the Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award for work on the interaction of pathogens with their human hosts.
ITHACA, N.Y. - 5/20/05 - A Cornell University researcher won the Burroughs Wellcome Fund Investigators in Pathogenesis of Infectious Disease Award for work on the interaction of pathogens with their human hosts.
Dr. John Parker, assistant professor with the Baker Institute for Animal Health in the College of Veterinary Medicine at Cornell, received one of the 11 awards given out this year.
Parker's research details reoviruses that affect the upper respiratory and gastrointestinal tract in humans and selectively kills cancer cells.
"We are seeking to understand the molecular mechanisms that underlie the ability of mammalian reoviruses to preferentially kill certain types of cancer cells," Parker says in a prepared release.
There were 123 applicants nominated by universities for the award nationwide. The award offers $80,000 a year for five years to researchers without tenure or those within five years of receiving tenure.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More